Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] price plunged by -10.03 percent to reach at -$50.16.
The one-year VRTX stock forecast points to a potential upside of 11.91. The average equity rating for VRTX stock is currently 2.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Vertex Pharmaceuticals, Inc [VRTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VRTX shares is $510.85 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VRTX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Leerink Partners have made an estimate for Vertex Pharmaceuticals, Inc shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on May-07-25. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on April 22, 2025, representing the official price target for Vertex Pharmaceuticals, Inc stock. Previously, the target price had yet another raise from $408 to $424, while Canaccord Genuity kept a Hold rating on VRTX stock.
The Average True Range (ATR) for Vertex Pharmaceuticals, Inc is set at 17.67, with the Price to Sales ratio for VRTX stock in the period of the last 12 months amounting to 10.45. The Price to Book ratio for the last quarter was 7.01, with the Price to Cash per share for the same quarter was set at 24.12.
VRTX Stock Performance Analysis:
Vertex Pharmaceuticals, Inc [VRTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.62. With this latest performance, VRTX shares dropped by -5.18% in over the last four-week period, additionally sinking by -5.45% over the last 6 months – not to mention a rise of 12.46% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VRTX stock in for the last two-week period is set at 32.17, with the RSI for the last a single of trading hit 25.32, and the three-weeks RSI is set at 37.04 for Vertex Pharmaceuticals, Inc [VRTX]. The present Moving Average for the last 50 days of trading for this stock 491.74, while it was recorded at 491.95 for the last single week of trading, and 471.38 for the last 200 days.
Insight into Vertex Pharmaceuticals, Inc Fundamentals:
Vertex Pharmaceuticals, Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.29 and a Current Ratio set at 2.65.
Vertex Pharmaceuticals, Inc [VRTX] Institutonal Ownership Details
The top three institutional holders of VRTX stocks are: CAPITAL WORLD INVESTORS with ownership of 26.71 million shares, which is approximately 10.3479%. VANGUARD GROUP INC, holding 22.98 million shares of the stock with an approximate value of $$10.77 billion in VRTX stocks shares; and VANGUARD GROUP INC, currently with $$9.99 billion in VRTX stock with ownership which is approximately 8.2574%.
